Anti-aging medicine is characterised by significant ‘hype’, hope and promise. This article examines the conditions giving rise to and sustaining this field. It questions its key premises, highlights the politico-economic ‘drivers’ of its innovations, and identifies the key actor networks sustaining its practices. As the article argues, it is highly questionable whether the viability of anti-aging medicine can be sustained as a discrete field of practice in the longer term. The instability of this field stems from its reliance on a faulty epistemological premise: that aging is a disease requiring technological intervention. In addition, anti-aging medicine is dependent on a series of fragile links and destabilising tendencies that threaten its long-term future. As sweeping promises regarding the ‘revolutionary’ potential of anti-aging medicine are made, financial, industry, government and public support becomes ever more contingent upon those utopian promises being realised. For reasons we discuss, this may not be possible. The article concludes by exploring the future of anti-aging medicine, highlighting a number of potential alternative scenarios.
This is a preview of subscription content, access via your institution.
http://www.mrc.ac.uk/Ourresearch/priorities/index.htm; accessed 9 March 2009.
http://www.bbsrc.ac.uk/funding/priorities.html; accessed 9 March 2009.
http://www.bbsrc.ac.uk/science/topical/ageing.html; accessed 9 March 2009.
http://www.nia.nih.gov/AboutNIA/; accessed 21 March 2009.
In this context, ‘medicalisation’ refers to the practice whereby ordinary processes of the body (such as menstruation, menopause or aging) come to be re-defined by the medical profession as ‘medical problems’ warranting professional analysis and treatment (Nettleton 1995, p. 27), rather than in the sense scholars such as Conrad (1992) use the term, to describe the process of framing deviant behaviours (such as homosexuality) in medical terms.
http://www.worldhealth.net/pages/a4m_s_mission; accessed 23 February 2009.
http://www.worldhealthnet.tv; accessed 23 February 2009.
For example, at least one researcher profiled in an article about the anti-aging enterprise, written by Abraham (2009), insisted that all profits made by a company he founded be put back into clinical research.
This is not necessarily a new phenomenon; indeed, as Haber (2004) notes, there is evidence of some physicians making considerable financial gain from anti-ageing treatments in the early twentieth century.
Abraham, C. 2009. The quest for the test tube of youth. The Globe and Mail, January 10.
Alexander, B. 2008. Selling longer life—or snake oil? http://www.msnbc.msn.com/id/23358976/. Accessed 9 Mar 2009.
Brown, N. 2003. Hope against hype—accountability in biopasts, presents and futures. Science Studies 16 (2): 3–21.
Calasanti, T. 2007. Bodacious berry, potency wood and the aging monster: Gender and age relations in anti-aging ads. Social Forces 86 (1): 335–355.
Cientifica. 2008. Nanotechnology opportunity report, 3rd ed. London: Cientifica Ltd.
Conrad, P. 1992. Medicalization and social control. Annual Review of Sociology 18: 209–232.
Deb, K.D., A.D. Jayaprakash, V. Sharma, and S. Totey. 2007. Embryonic stem cells: From markers to market. Rejuvenation Research 11: 1.
Department of Health. 2003. Our inheritance, our future: Realising the potential of genetics in the NHS. Norwich: HMSO.
Drug Week. 2009. Scientists unlock possible aging secret in genetically altered fruit fly, February 20.
Ebeling, M. 2008. Mediating uncertainty: Communicating the financial risks of nanotechnologies. Science Communication 29 (3): 335–361.
Encyclopedia of Emerging Industries. 2007. Encyclopedia of emerging industries, 5th ed. Detroit: Thomson Gale.
Elliott, C. 2003. Better than well: American medicine meets the American dream. New York: W.W. Norton and Company.
Euromonitor International. 2006. World consumer spending 2006/2007, 7th ed. London: Euromonitor International.
Farrelly, C. 2008. Analysis: Has the time come to take on time itself? British Medical Journal 337: a414.
Fishman, J.R., R.H. Binstock, and M.A. Lambrix. 2008. Anti-aging science: The emergence, maintenance, and enhancement of a discipline. Journal of Aging Studies 22: 295–303.
Gieryn, T.F. 1999. Cultural boundaries of science: Credibility on the line. Chicago: University of Chicago Press.
Gifford-Jones, W. 2009. Anti-aging benefits found in red wine pill—you can eat fat and live as long as the French, Winnipeg Free Press, February 20.
Gottweis, H., and A. Petersen (eds.). 2008. Biobanks: Governance in comparative perspective. London and New York: Routledge.
Haber, C. 2004. Life extension and history: The continual search for the fountain of youth. Journal of Gerontology: Biological Sciences 59A (6): 515–522.
Hayflick, L. 2004. “Anti-aging” is an oxymoron. Journal of Gerontology 59A (6): 573–578.
Holliday, R. 2009. The extreme arrogance of anti-aging medicine. Biogerontology 10: 223–228.
Holstein, M., and M. Minkler. 2003. Self, society and the “New Gerontology”. The Gerontologist 43: 787–797.
Houlton, S. 2008. British biotech blues. http://pharmexec.findpharma.com/pharmexec/Global+Report/British-Biotech-Blues/ArticleStandard/Article/detail/507982?contextCategoryId=124.
House of Lords Science and Technology Committee. 2005. First report of session 2005–2006: Ageing: Scientific Aspects. http://www.publications.parliament.uk/pa/ld200506/ldselect/ldsctech/20/20i.pdf. Accessed 19 Mar 2009.
Hughes, J.J. 2007. The struggle for a smarter world. Futures 39: 942–954.
Jasanoff, S. 2005. Designs on nature: Science and democracy in Europe and the United States. Princeton, NJ: Princeton University Press.
Jatmiko, I.S. 2009. In the search for youthful looks, The Jakarta Post, February 22.
Katz, S. 2001/2002. Growing older without aging? Positive aging, anti-ageism, and anti-aging. Generations 25 (4): 27–32.
Kohlbacher, F., and C. Herstatt (eds.). 2008. The silver market phenomenon: Business opportunities in an era of demographic change. Berlin: Springer.
Langreth, R. 2009. Biotech blues, Forbes Magazine, January 12. http://www.forbes.com/forbes/2009/0112/090.html. Accessed 21 Mar 2009.
Leith, S. 2009. Anti-ageing sales are built on lies and self-loathing, The Age, March 8.
Loe, M. 2004. The rise of Viagra: How the little blue pill changes sex in America. New York: New York University press.
Lux Research. 2004. The nanotech report 2004: Investment overview and market research for nanotechnology, 3rd ed. New York: Lux Research.
McManus, J. 2009. Hormone replacement—it’ll keep you “frisky”, The Independent, February 19.
Mehlman, M., R.H. Binstock, E.T. Juengst, R.S. Ponsaran, and P.J. Whitehouse. 2004. Anti-aging medicine: Can consumers be better protected? The Gerontologist 44 (3): 304–310.
Micans, P. 2005. The need for anti-aging medicine: the challenges faced to incorporate preventive medicine into the clinic and into society. Annals of the New York Academy of Sciences 1057: 545–562.
Minkler, M., and Estes, C. 1991. Critical perspectives on aging. Baywood Publishing Company: Amityville, New York.
Moynihan, R., and A. Cassels. 2005. Selling sickness: How drug companies are turning us all into patients. Crowsnest, Sydney: Allen and Unwin.
Mykytyn, C.E. 2006. Contentious terminology and complicated cartography of anti-aging medicine. Biogerontology 7: 279–285.
Mykytyn, C.E. 2008. Medicalizing the optimal: Anti-aging medicine and the quandary of intervention. Journal of Aging Studies 22: 313–321.
National Health and Medical Research Council. 2007. Research funding facts book May 2007. Canberra: Australian Government.
National Health and Medical Research Council. 2008. The ageing dataset. http://www.nhmrc.gov.au/grants/dataset/issues/ageing.php. Accessed 21 Mar 2009.
National Institutes of Health. 2001. Stem cells: Scientific progress and future research directions. Washington, DC: Department of Human Services and Health.
National Science Foundation. 2001. Societal implication of nanoscience and nanotechnology. http://www.wtec.org/loyola/nano/NSET.Societal.Implications/.
Nettleton, S. 1995. The sociology of health and illness, 1st ed. Cambridge: Polity Press.
Pálsson, G. 2008. The rise and fall of a biobank: The case of Iceland. In Biobanks: Governance in comparative perspective, ed. H. Gottweis, and A. Petersen, 41–55. London and New York: Routledge.
Petersen, A. 2006. The genetic conception of health: Is it as radical as claimed? Health 10 (4): 481–500.
Petersen, A. 2007. The body in question: A socio-cultural approach. London and New York: Routledge.
Petersen, A., A. Anderson, C. Wilkinson, S. Allan. 2008. Opening the black box: Scientists’ views on the role of the news media in the nanotechnology debate. Public Understanding of Science (published online first). http://pus.sagepub.com/cgi/rapidpdf/0963662507084202v1.
Robert, L. 2004. The three avenues of gerontology: From basic research to clinical gerontology and anti-aging medicine. Another French paradox. Journal of Gerontology: Biological Sciences 59A (6): 540–542.
Roberts, P. 2009. A sector in need of strong medicine, The Weekend Australian Financial Review, March 14–15: 14.
Royal Society and Royal Academy of Engineering. 2004. Nanoscience and nanotechnologies: Opportunities and uncertainties. London: RS-RAE.
Rudman, D. 2006. Shaping the active, autonomous and responsible modern retiree: An analysis of discursive technologies and their links with neo-liberal political rationality. Ageing and Society 26: 181–201.
Seear, K., A. Petersen, and D. Bowman. 2009. The social and economic impacts of nanotechnologies: A literature review. Clayton: Monash University.
Settersen, R.A., M.A. Flatt, and R. Ponsaran. 2008. From the lab to the front line: How individual biogerontologists navigate their contested field. Journal of Aging Studies 22: 304–312.
Storz, P., H. Gothe, A. Daroszewska, and B. Häussler. 2008. Innovative health technologies in the “anti-aging” medicine field: Results from a systematic horizon scanning. Berlin: IGES Institut GmbH. 8–11 November. http://www.iges.de/publikationen/poster__abstracts/ispor_athen/e7007/infoboxContent7009/Poster_2_L248-033_ger.pdf. Accessed 26 Mar 2009.
The Cairns Eye. 2009. Science has finally found the fountain of youth with regenerative medicine, February 18.
Turner, L. 2004. Biotechnology bioethics and anti-aging interventions. Trends in Biotechnology 22 (5): 219–221.
Underwood, M., H. Bartlett, and W. Hall. 2007. Community attitudes to the regulation of life extension. Annals of the New York Academy of Sciences 1114: 288–299.
Vincent, J.A. 2008. The cultural construction of old age as a biological phenomenon: Science and anti-ageing technologies. Journal of Aging Studies 22: 331–339.
Vincent, J.A., E. Tulle, and J. Bond. 2008. The anti-aging enterprise: Science, knowledge, expertise, rhetoric and values. Journal of Aging Studies 22: 291–294.
Webster, T.J. 2008. Projections for nanomedicine into the next decade: but is it all about pharmaceuticals. International Journal of Nanomedicine 3 (1): i.
Weintraub, A. 2006. Selling the promise of youth. Business Week 3976: 6.
Wick, G. 2002. Anti-aging medicine does it exist?: A critical discussion of anti-aging health projects. Experimental Gerontology 37: 1137–1140.
Wolf, A. 2005. What is anti-aging medicine? Hautarzt 56: 315–320.
World Health Organization. 2002a. Genomics and world health. Report of the Advisory Committee on Health Research. Geneva: WHO.
World Health Organization. 2002b. Active ageing: A policy framework. Geneva: WHO.
Yu, B.P. 1999. Approaches to anti-aging intervention: the promises and the uncertainties. Mechanisms of Aging and Development 111: 73–87.
About this article
Cite this article
Petersen, A., Seear, K. In Search of Immortality: The Political Economy of Anti-aging Medicine. Medicine Studies 1, 267 (2009). https://doi.org/10.1007/s12376-009-0020-x
- Anti-aging medicine
- Pharmaceutical industry
- Politico-economic ‘drivers’
- ‘Grey market’